Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization
Front Pharmacol. 2022 Jun 7;13:905936. doi: 10.3389/fphar.2022.905936.
Article
Jun 07, 2022